Challenges in the development of prescription opioid abuse-deterrent formulations

Nathaniel P. Katz, Edgar H. Adams, Howard Chilcoat, Robert D. Colucci, Sandra D. Comer, Philip Goliber, Charles Grudzinskas, Donald Jasinski, Stephen D. Lande, Steven D. Passik, Sidney H. Schnoll, Edward Sellers, Debra Travers, Roger Weiss

Research output: Contribution to journalArticle

Abstract

Opioid analgesics remain the cornerstone of effective management for moderate-to-severe pain. In the face of persistent lack of access to opioids by patients with legitimate pain problems, the rate of prescription opioid abuse in the United States has escalated over the past 15 years. Abuse-deterrent opioid products can play a central role in optimizing the risk-benefit ratio of opioid analgesics-if these products can be developed cost-effectively without compromising efficacy or creating new safety issues for the target treatment population. The development of scientific methods for assessing prescription opioid abuse potential remains a critical and challenging step in determining whether a claim of abuse deterrence for a new opioid product is indeed valid and will thus be accepted by the medical, regulatory, and reimbursement communities. To explore this and other potential impediments to the development of prescription opioid abuse-deterrent formulations, a panel of experts on opioid abuse and diversion from academia, industry, and governmental agencies participated in a Tufts Health Care Institute-supported symposium held on October 27 and 28, 2005, in Boston, MA. This manuscript captures the main consensus opinions of those experts, and also information gleaned from a review of the relevant published literature, to identify major impediments to the development of opioid abuse-deterrent formulations and offer strategies that may accelerate their commercialization.

Original languageEnglish (US)
Pages (from-to)648-660
Number of pages13
JournalClinical Journal of Pain
Volume23
Issue number8
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Opioid Analgesics
Prescriptions
Pain
Health Services Needs and Demand
Expert Testimony
Consensus
Industry
Odds Ratio
Delivery of Health Care
Safety
Costs and Cost Analysis

Keywords

  • Abuse-deterrent
  • Abuse-resistant
  • Opioid analgesics
  • Prescription opioid abuse

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Clinical Neurology

Cite this

Katz, N. P., Adams, E. H., Chilcoat, H., Colucci, R. D., Comer, S. D., Goliber, P., ... Weiss, R. (2007). Challenges in the development of prescription opioid abuse-deterrent formulations. Clinical Journal of Pain, 23(8), 648-660. https://doi.org/10.1097/AJP.0b013e318125c5e8

Challenges in the development of prescription opioid abuse-deterrent formulations. / Katz, Nathaniel P.; Adams, Edgar H.; Chilcoat, Howard; Colucci, Robert D.; Comer, Sandra D.; Goliber, Philip; Grudzinskas, Charles; Jasinski, Donald; Lande, Stephen D.; Passik, Steven D.; Schnoll, Sidney H.; Sellers, Edward; Travers, Debra; Weiss, Roger.

In: Clinical Journal of Pain, Vol. 23, No. 8, 10.2007, p. 648-660.

Research output: Contribution to journalArticle

Katz, NP, Adams, EH, Chilcoat, H, Colucci, RD, Comer, SD, Goliber, P, Grudzinskas, C, Jasinski, D, Lande, SD, Passik, SD, Schnoll, SH, Sellers, E, Travers, D & Weiss, R 2007, 'Challenges in the development of prescription opioid abuse-deterrent formulations', Clinical Journal of Pain, vol. 23, no. 8, pp. 648-660. https://doi.org/10.1097/AJP.0b013e318125c5e8
Katz, Nathaniel P. ; Adams, Edgar H. ; Chilcoat, Howard ; Colucci, Robert D. ; Comer, Sandra D. ; Goliber, Philip ; Grudzinskas, Charles ; Jasinski, Donald ; Lande, Stephen D. ; Passik, Steven D. ; Schnoll, Sidney H. ; Sellers, Edward ; Travers, Debra ; Weiss, Roger. / Challenges in the development of prescription opioid abuse-deterrent formulations. In: Clinical Journal of Pain. 2007 ; Vol. 23, No. 8. pp. 648-660.
@article{b0d797dec2d34715b1a42151ba6b751f,
title = "Challenges in the development of prescription opioid abuse-deterrent formulations",
abstract = "Opioid analgesics remain the cornerstone of effective management for moderate-to-severe pain. In the face of persistent lack of access to opioids by patients with legitimate pain problems, the rate of prescription opioid abuse in the United States has escalated over the past 15 years. Abuse-deterrent opioid products can play a central role in optimizing the risk-benefit ratio of opioid analgesics-if these products can be developed cost-effectively without compromising efficacy or creating new safety issues for the target treatment population. The development of scientific methods for assessing prescription opioid abuse potential remains a critical and challenging step in determining whether a claim of abuse deterrence for a new opioid product is indeed valid and will thus be accepted by the medical, regulatory, and reimbursement communities. To explore this and other potential impediments to the development of prescription opioid abuse-deterrent formulations, a panel of experts on opioid abuse and diversion from academia, industry, and governmental agencies participated in a Tufts Health Care Institute-supported symposium held on October 27 and 28, 2005, in Boston, MA. This manuscript captures the main consensus opinions of those experts, and also information gleaned from a review of the relevant published literature, to identify major impediments to the development of opioid abuse-deterrent formulations and offer strategies that may accelerate their commercialization.",
keywords = "Abuse-deterrent, Abuse-resistant, Opioid analgesics, Prescription opioid abuse",
author = "Katz, {Nathaniel P.} and Adams, {Edgar H.} and Howard Chilcoat and Colucci, {Robert D.} and Comer, {Sandra D.} and Philip Goliber and Charles Grudzinskas and Donald Jasinski and Lande, {Stephen D.} and Passik, {Steven D.} and Schnoll, {Sidney H.} and Edward Sellers and Debra Travers and Roger Weiss",
year = "2007",
month = "10",
doi = "10.1097/AJP.0b013e318125c5e8",
language = "English (US)",
volume = "23",
pages = "648--660",
journal = "Clinical Journal of Pain",
issn = "0749-8047",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Challenges in the development of prescription opioid abuse-deterrent formulations

AU - Katz, Nathaniel P.

AU - Adams, Edgar H.

AU - Chilcoat, Howard

AU - Colucci, Robert D.

AU - Comer, Sandra D.

AU - Goliber, Philip

AU - Grudzinskas, Charles

AU - Jasinski, Donald

AU - Lande, Stephen D.

AU - Passik, Steven D.

AU - Schnoll, Sidney H.

AU - Sellers, Edward

AU - Travers, Debra

AU - Weiss, Roger

PY - 2007/10

Y1 - 2007/10

N2 - Opioid analgesics remain the cornerstone of effective management for moderate-to-severe pain. In the face of persistent lack of access to opioids by patients with legitimate pain problems, the rate of prescription opioid abuse in the United States has escalated over the past 15 years. Abuse-deterrent opioid products can play a central role in optimizing the risk-benefit ratio of opioid analgesics-if these products can be developed cost-effectively without compromising efficacy or creating new safety issues for the target treatment population. The development of scientific methods for assessing prescription opioid abuse potential remains a critical and challenging step in determining whether a claim of abuse deterrence for a new opioid product is indeed valid and will thus be accepted by the medical, regulatory, and reimbursement communities. To explore this and other potential impediments to the development of prescription opioid abuse-deterrent formulations, a panel of experts on opioid abuse and diversion from academia, industry, and governmental agencies participated in a Tufts Health Care Institute-supported symposium held on October 27 and 28, 2005, in Boston, MA. This manuscript captures the main consensus opinions of those experts, and also information gleaned from a review of the relevant published literature, to identify major impediments to the development of opioid abuse-deterrent formulations and offer strategies that may accelerate their commercialization.

AB - Opioid analgesics remain the cornerstone of effective management for moderate-to-severe pain. In the face of persistent lack of access to opioids by patients with legitimate pain problems, the rate of prescription opioid abuse in the United States has escalated over the past 15 years. Abuse-deterrent opioid products can play a central role in optimizing the risk-benefit ratio of opioid analgesics-if these products can be developed cost-effectively without compromising efficacy or creating new safety issues for the target treatment population. The development of scientific methods for assessing prescription opioid abuse potential remains a critical and challenging step in determining whether a claim of abuse deterrence for a new opioid product is indeed valid and will thus be accepted by the medical, regulatory, and reimbursement communities. To explore this and other potential impediments to the development of prescription opioid abuse-deterrent formulations, a panel of experts on opioid abuse and diversion from academia, industry, and governmental agencies participated in a Tufts Health Care Institute-supported symposium held on October 27 and 28, 2005, in Boston, MA. This manuscript captures the main consensus opinions of those experts, and also information gleaned from a review of the relevant published literature, to identify major impediments to the development of opioid abuse-deterrent formulations and offer strategies that may accelerate their commercialization.

KW - Abuse-deterrent

KW - Abuse-resistant

KW - Opioid analgesics

KW - Prescription opioid abuse

UR - http://www.scopus.com/inward/record.url?scp=34648813683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34648813683&partnerID=8YFLogxK

U2 - 10.1097/AJP.0b013e318125c5e8

DO - 10.1097/AJP.0b013e318125c5e8

M3 - Article

C2 - 17885342

AN - SCOPUS:34648813683

VL - 23

SP - 648

EP - 660

JO - Clinical Journal of Pain

JF - Clinical Journal of Pain

SN - 0749-8047

IS - 8

ER -